Recombinant human BAFF (B-cell-activating factor, also known as TNFSF13B, Tumor necrosis factor ligand superfamily member 13B), encompassing amino acids 134-285. This construct contains an N-terminal His-tag (6xHis) followed by an Avi-Tag™. The recombinant protein was affinity purified.
●
Synonyms
TNFSF13B, Tumor necrosis factor ligand superfamily member 13B, DTL, BAFF, B lymphocyte stimulator, BLYS, CD257, TNF- and APOL-related leukocyte expressed ligand 1, TALL1, TALL-1, THANK, ZTNF4, TNLG7A, TNFSF20
●
Product Data Gallery
4-20% SDS-PAGE Coomassie Staining
BAFF:BCMA[Biotinylated] Binding
BAFF: BCMA[Biotinylated] inhibition curve using a chemiluminescent assay (#79667). Representative data only; data may vary by lot.
8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
MW
20 kDa + glycans
Amino Acids
134-285(end)
Glycosylation
This protein runs at a higher MW by SDS-PAGE due to glycosylation.
Genbank #
NM_006573
UniProt #
Q9Y275
Tag(s)
N-terminal His-Avi-Tag
Background
B-cell activating factor (BAFF) is a cytokine regulating B cell development, survival, and antibody production. It is a key player in the immune response and has implications in autoimmune diseases. It is a ligand for receptors TNFRSF13B/TACI, TNFRSF17/BCMA, and TNFRSF13C/BAFFR. BAFF normally maintains immune balance, and overproduction of BAFF leads to various auto-immune diseases. It is, therefore, a therapeutic target. Drugs that inhibit BAFF, such as belimumab, have been approved for the treatment of certain autoimmune disorders.
2. Hever, A., et al. Proc. Natl. Acad. Sci. U.S.A. 104 (30), 12451-12456 (2007)
Storage/Stability
At least 6 months at –80°C
Instructions for Use
Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.
Applications
Useful for binding studies and screening inhibitors of ligand binding to its receptor.